avail
immunomemin
tool
fuel
design
develop
vaccin
process
come
term
revers
vaccinolog
vaccinom
immunomederiv
vaccin
idv
design
genomederiv
vaccin
design
rappuoli
covacci
petrovski
brusic
pederson
de
groot
martin
doytchinova
taylor
flower
vaccin
concept
base
identif
minim
set
antigen
induc
compet
immun
respons
pathogen
neoplasm
recognit
antigen
occur
present
b
cell
cell
epitop
deriv
antigen
correct
immunolog
milieu
minim
form
idv
would
contain
adjuvan
b
cell
cell
epitop
deliveri
vehicl
liposom
minim
compon
packag
appropri
deliveri
vehicl
complet
packag
compris
idv
compar
tradit
vaccin
idv
potenti
safer
effect
sinc
vaccin
focus
protect
immun
respons
essenti
antigen
element
pathogenneoplasm
number
idv
test
clinic
trial
elliott
gaheri
et
al
et
al
kran
et
al
epitopebas
idv
gener
consid
safe
compar
vector
attenu
live
vaccin
mani
progress
rapidli
preclin
concept
clinic
trial
cancer
vaccin
field
epitopebas
vaccin
wellestablish
mani
vaccin
current
phase
iii
clinic
trial
pietersz
pounioti
apostolopoulo
chapter
review
develop
valid
idv
also
provid
stepbystep
guid
develop
idv
use
valid
immunoinformat
tool
tool
potenti
dramat
acceler
develop
new
improv
vaccin
emerg
exist
infecti
diseas
wholeantigenbas
idv
cover
briefli
howev
main
focu
epitopebas
idv
descript
immunoinformat
tool
develop
acceler
preclin
phase
vaccin
discoveri
illustr
process
preclin
vaccin
develop
use
tool
two
epitopebas
idv
case
studi
present
genomederiv
vaccin
tularemia
ii
epitopebas
hpv
vaccin
adjunct
treatment
cancer
size
immunom
puzzl
vaccinologist
decad
certainli
exampl
literatur
singl
epitop
protect
exampl
crow
et
al
recent
found
immun
singl
th
epitop
provid
onelog
reduct
influenza
viral
titer
earli
infect
singl
epitop
also
shown
protect
viral
diseas
woodchuck
menn
et
al
multipl
singl
epitop
protect
mice
array
pathogen
whitton
olsen
et
al
divers
set
cell
epitop
appear
critic
immun
respons
vaccinia
mice
class
mhc
epitop
shown
contribut
larg
major
cell
immun
respons
moutaftsi
et
al
remark
found
predict
epitop
deriv
candid
repres
vacciniaspecif
cell
repertoir
number
might
extrapol
human
unknown
result
relev
epitop
enough
easili
packag
deliv
vaccin
epitopebas
idv
genet
divers
popul
human
almost
certainli
requir
number
epitop
particularli
vaccin
intend
protect
complex
bacteria
virus
solid
tumor
present
variabl
antigen
profil
har
power
immunoinformat
acceler
task
defin
immunom
identifi
develop
new
vaccin
human
diseas
select
target
organ
next
step
immunometovaccin
process
identifi
within
target
genom
set
potenti
antigen
genesprotein
sequenc
screen
use
varieti
silico
vitro
vivo
mechan
combin
method
case
small
viral
genom
may
possibl
includ
entir
genom
search
univers
case
larger
bacteri
viral
pathogen
tradit
vaccin
target
includ
surfac
protein
secret
protein
easili
found
use
silico
screen
program
toxin
identifi
homolog
match
virul
factor
identifi
use
compar
genom
howev
mani
type
protein
may
also
worthi
consider
particular
protein
express
high
amount
viral
capsid
protein
protein
overexpress
growth
replic
protein
overexpress
respons
stress
condit
cancer
vaccin
comparison
cancer
normal
tissu
uncov
cancerspecif
gene
one
approach
involv
use
mrna
deriv
cancer
normal
tissu
probe
dna
microarray
follow
select
gene
upregul
cancer
normal
tissu
mathiassen
et
al
sepkowitz
use
revers
vaccinolog
term
recent
coin
rino
rappuoli
immun
memori
subject
success
encount
defeat
pathogen
interrog
identifi
primari
target
natur
immun
respons
rappuoli
colleagu
identifi
novel
vaccin
target
use
silico
techniqu
screen
target
genom
surfac
proteinlik
sequenc
candid
protein
express
escherichia
coli
screen
human
sera
isol
pathogenexpos
subject
reactiv
protein
deem
relev
immun
respons
pizza
et
al
relat
approach
discov
candid
vaccin
antigen
involv
analyz
target
pathogen
proteom
silico
use
cell
epitop
map
tool
put
cell
epitop
identifi
screen
peripher
blood
mononuclear
cell
pbmc
isol
human
subject
infect
target
pathogen
target
cancer
cell
reaction
particular
peptid
epitop
typic
measur
elisa
elispot
assay
impli
protein
peptid
deriv
express
process
present
immun
system
cours
natur
immun
respons
use
method
measur
immun
respons
epitop
reveal
protein
antigen
group
describ
approach
fish
antigen
use
epitop
bait
common
vitro
techniqu
use
identifi
express
overexpress
genesprotein
includ
sdspage
kaufmann
et
al
sonnenberg
belisl
hernychova
et
al
mass
spectrometri
tomlinson
jameson
naylor
andor
tandem
mass
spectrometri
barnea
et
al
context
vaccin
infecti
diseas
may
prudent
exclud
protein
highli
conserv
across
speci
protein
includ
housekeep
gene
may
crossreact
unrel
avirul
organ
selfprotein
may
preexist
toler
howev
conserv
across
speci
confus
conserv
within
speci
variant
sequenc
conserv
within
speci
variant
highli
desir
trait
vaccin
compon
one
idv
approach
particularli
well
suit
har
rna
virus
particular
hcv
hiv
coronavirus
highli
variabl
pathogen
case
select
epitop
conserv
across
variant
subtyp
may
allow
develop
broadli
applic
vaccin
altern
singl
protein
rel
well
conserv
compar
balanc
target
pathogen
select
vaccin
candid
recent
exampl
one
team
develop
hexonepitop
vaccin
may
effect
rang
adenovirus
across
serotyp
leen
et
al
critic
antigen
identifi
next
step
epitopebas
idv
develop
select
epitop
confirm
immunogen
adapt
immun
system
engag
humor
antibodybas
respons
form
first
line
defens
viral
bacteri
pathogen
antibodi
recogn
b
cell
epitop
compos
either
linear
peptid
sequenc
conform
determin
present
threedimension
form
antigen
sever
b
cell
epitop
predict
tool
cep
propos
process
refin
enshellseijff
et
al
schreiber
et
al
kulkarni
et
al
unfortun
comput
resourc
model
complex
requir
predict
b
cell
epitop
enorm
complex
due
part
inher
flexibl
complementar
determin
region
cdr
antibodi
part
due
glycosyl
posttransl
modif
result
modif
b
cell
epitop
although
accur
b
cell
epitop
map
tool
remain
elus
select
potent
b
cell
antigen
acceler
use
cell
epitop
map
tool
consid
b
cell
antigen
potenti
subunit
vaccin
may
import
also
consid
cell
epitop
content
sinc
qualiti
kinet
antibodi
respons
depend
upon
presenc
help
b
cell
antigen
contain
signific
help
may
outperform
b
cell
antigen
lack
cognat
help
case
identifi
cell
epitop
may
contain
b
cell
epitop
although
differ
epitop
activ
b
cell
wide
report
b
cell
epitop
shown
coloc
near
overlap
class
ii
th
epitop
graham
et
al
rajnavolgyi
et
al
identifi
peptid
repres
select
epitop
synthes
hla
bind
assay
use
assess
whether
peptid
deriv
immunoinformat
analysi
bind
either
mhc
class
class
ii
measur
affin
predict
epitop
sequenc
hla
allel
vitro
vitro
evalu
mhc
bind
perform
quantifi
abil
exogen
ad
peptid
compet
fluoresc
label
known
mhc
ligand
steer
et
al
adapt
high
throughput
mcmurri
et
al
epivax
routin
use
highthroughput
hla
bind
assay
confirm
epitop
predict
vitro
concord
hla
bind
immunogen
often
observ
mcmurri
et
al
peptid
use
measur
cell
respons
vitro
variabl
length
peptid
present
context
class
mhc
gener
limit
amino
acid
length
although
process
believ
occur
cell
assay
also
use
class
assay
contrast
class
epitop
short
fit
tightli
bound
mhc
molecul
class
ii
helper
epitop
lie
within
openend
groov
mhc
ii
class
ii
epitop
shift
within
groov
therebi
accommod
mhc
variou
haplotyp
limit
size
peptid
abil
remain
linear
conform
openend
groov
mhc
class
mhc
class
iirestrict
epitop
target
cell
respect
believ
import
develop
effect
vaccin
helper
cell
enhanc
amplifi
cytotox
cell
ctl
immun
respons
shown
import
develop
cell
memori
rang
pathogen
ahler
et
al
ctl
gener
play
role
contain
viral
bacteri
infect
plotnicki
et
al
preval
ctl
usual
correl
rate
pathogen
clearanc
like
peptid
whole
antigen
use
measur
cell
respons
vitro
recognit
antigen
requir
presenc
apc
capabl
process
present
peptid
deriv
antigen
blood
expos
individu
avail
peptid
valid
mhc
ligand
bind
assay
test
reactiv
cell
serum
posit
immun
respons
measur
elisa
elispot
intracellular
cytokin
stain
interpret
sign
parent
protein
interfac
host
immun
respons
cours
natur
infect
diseas
follow
confirm
peptid
stimul
respons
consid
vaccin
candid
use
select
entir
protein
use
subunit
vaccin
candid
incorpor
vaccin
deliveri
vehicl
appropri
adjuv
elisa
elispot
relat
method
detect
cell
respons
measur
cytokin
secret
cell
gamma
interferon
exampl
expans
prolifer
cell
respons
stimul
peptid
mhc
measur
dilut
fluoresc
dye
subsequ
gener
cell
cfse
incorpor
radioact
label
prolifer
cell
dna
tritiat
thymidin
incorpor
assay
fluoresc
activ
cell
sort
fac
intracellular
cytokin
stain
ic
precis
methodolog
avail
measur
defin
cell
respons
exampl
cell
respond
particular
epitop
directli
label
use
tetram
compris
mhc
class
ii
peptid
complex
label
cell
sort
count
phenotyp
cell
respond
antigen
determin
use
cell
surfac
marker
ic
toberi
et
al
factor
extrins
process
cytokin
milieu
induc
respons
particular
compon
vaccin
krieg
et
al
pathogen
ghosh
et
al
also
play
role
condit
immun
respons
thu
cell
epitop
may
necessari
drive
immun
respons
suffici
costimulatori
molecul
provid
second
signal
right
cytokin
milieu
factor
direct
natur
vs
immun
respons
also
crucial
shahinian
et
al
kuchroo
et
al
adjuv
provid
ad
boost
context
vaccin
rang
deliveri
vehicl
exist
convent
vaccin
use
develop
idv
epitopebas
idv
exampl
idv
epitopebas
idv
formul
deliv
pseudoprotein
peptid
carrier
vehicl
liposom
virallik
protein
vlp
altern
sequenc
idv
antigen
epitop
string
insert
viral
bacteri
vector
adenoviru
salmonella
altern
dna
vaccin
construct
encod
antigen
epitop
develop
choic
adjuv
use
human
rel
extens
adjuv
advantag
disadvantag
advantag
disadvantag
type
vaccin
deliveri
vehicl
adjuv
beyond
scope
chapter
reader
refer
review
fraser
et
al
next
step
develop
epitopedriven
idv
determin
whether
immun
provid
compet
immun
respons
idv
epitopebas
idv
administ
immun
respons
compon
evalu
follow
immun
even
though
rang
anim
model
use
evalu
vaccin
result
immunogen
studi
model
interpret
caution
although
function
may
similar
mhc
mice
rodent
nonhuman
primat
differ
human
mhc
known
hla
context
human
immun
respons
amino
acid
level
differ
effect
epitop
present
help
explain
differ
strain
mice
balbc
differ
immun
respons
pathogen
well
vaccin
pathogen
klitgaard
et
al
particular
epitopebas
vaccin
develop
use
predict
human
cell
epitop
map
tool
test
murin
model
hla
transgen
fortun
number
transgen
mous
strain
express
common
hla
hla
b
hla
dr
molecul
develop
cell
respons
mice
correl
directli
cell
respons
observ
infectedvaccin
human
man
et
al
shirai
et
al
hla
transgen
mice
routin
use
assay
optim
human
epitopedriven
vaccin
preclin
studi
ishioka
et
al
charo
et
al
livingston
et
al
despit
limit
number
hla
class
ii
allel
tg
mice
develop
comparison
immunogen
done
high
degre
accuraci
mous
model
select
hla
class
ii
allel
hla
dr
unfortun
appear
mice
may
difficulti
breed
due
poorli
understood
consequ
transgen
heritag
limit
use
import
model
system
final
step
develop
vaccin
experiment
valid
immunogen
protect
efficaci
comput
select
antigen
current
seri
experiment
vaccin
shown
efficaci
anim
model
sever
idv
test
clinic
studi
context
infecti
diseas
genomederiv
vaccin
progress
furthest
along
vaccin
develop
pipelin
gener
base
whole
protein
rather
epitop
rappuoli
covacci
pizza
et
al
howev
epitopebas
idv
current
develop
rang
infecti
diseas
author
laboratori
mani
other
depla
et
al
common
knowledg
subunitbas
vaccin
protect
infect
similar
success
epitopebas
approach
wide
known
addit
studi
previous
cite
immun
balbc
mice
three
dose
peptid
construct
contain
restrict
cytotox
lymphocyt
ctl
epitop
murin
malaria
parasit
induc
cell
prolifer
peptidespecif
ctl
respons
mediat
nitricoxidedepend
elimin
malariainfect
hepatocyt
vitro
well
partial
protect
balbc
mice
sporozoit
challeng
frank
et
al
separ
studi
immun
balbc
cba
mice
measl
viru
ctl
epitop
result
induct
epitopespecif
ctl
respons
confer
protect
enceph
follow
intracerebr
challeng
lethal
dose
viru
schadeck
et
al
success
exampl
mani
studi
carri
anim
model
howev
translat
prevent
diseas
human
difficult
achiev
contrast
wholeprotein
subunit
vaccin
idv
epitopebas
idv
taken
longer
make
transit
anim
model
clinic
mainli
due
novelti
concept
perhap
unfound
concern
epitop
suffici
gener
effect
immun
respons
cancer
therapi
except
rule
previous
describ
eptiopebas
idv
evalu
context
therapi
chronic
infect
cancer
ueda
et
al
valmori
et
al
cancer
vaccin
field
concept
epitopedriven
vaccin
well
establish
mani
peptid
vaccin
success
pass
preclin
test
current
phase
iii
clinic
trial
pietersz
pounioti
apostolopoulo
new
approach
emerg
may
improv
success
rate
inde
result
recent
clinic
trial
prove
principl
one
approach
identifi
epitop
uniqu
tumor
prostat
lung
colon
prescreen
patient
respons
peptid
approach
call
person
vaccin
take
account
divers
ctl
epitop
recognit
among
patient
wherea
respons
rate
classic
nonperson
peptid
vaccin
disappoint
respons
person
vaccin
phase
trial
conduct
japan
high
advanc
cancer
equal
malign
glioma
cervic
cancer
respect
itoh
yamada
noteworthi
epitopedriven
vaccin
viral
microbi
pathogen
reach
stage
phase
ii
efficaci
trial
human
exampl
bionor
immuno
hiv
gag
peptid
vaccin
demonstr
safe
well
toler
phase
trial
et
al
dosedepend
immunogen
phase
ii
trial
norway
kran
et
al
similarli
nardin
epitopebas
vaccin
malaria
move
along
clinic
trial
pathway
nardin
et
al
cell
epitop
linear
peptid
bind
mhc
molecul
bind
mediat
interact
rgroup
amino
acid
peptid
ligand
pocket
floor
mhc
bind
groov
mhc
peptid
interact
well
character
patternmatch
algorithm
use
screen
protein
sequenc
peptid
bind
mhc
author
report
current
use
epimatrix
system
suit
epitopemap
tool
valid
decad
use
select
put
epitop
vitro
vivo
studi
see
refer
de
groot
et
al
bond
et
al
dong
et
al
mcmurri
et
al
koita
et
al
epimatrix
algorithm
base
set
class
class
ii
hla
matric
wherein
individu
frequenc
amino
acid
aa
hla
pocket
posit
appli
predict
overlap
peptid
typic
analysi
protein
antigen
pars
overlap
frame
overlap
last
eight
amino
acid
score
predict
bind
affin
one
class
class
ii
hla
allel
order
compar
potenti
epitop
across
multipl
hla
allel
epimatrix
raw
score
convert
normal
z
scale
peptid
score
epimatrix
z
scale
typic
top
given
sampl
like
mhc
ligand
sinc
class
ii
epitop
promiscu
approach
predict
class
ii
epitop
estim
bind
potenti
frame
respect
panel
eight
common
class
ii
allel
taken
togeth
allel
cover
genet
background
human
worldwid
southwood
et
al
also
repres
predomin
type
pocket
common
mhc
recent
epimatrix
system
util
measur
potenti
immunogen
whole
protein
context
epimatrix
assess
aggreg
epitop
densiti
given
protein
respect
aggreg
epitop
densiti
set
randomli
gener
pseudoprotein
sequenc
similar
size
de
groot
correct
size
expect
epitop
densiti
potenti
immunogen
candid
vaccin
antigen
directli
compar
immunogen
low
score
protein
may
enhanc
modifi
immunogen
region
amino
acid
sequenc
contain
cell
epitop
see
illustr
approach
hpv
vaccin
section
peptid
predict
bind
multipl
hla
allel
known
promiscu
cell
epitop
clustim
algorithm
use
scan
output
produc
epimatrix
identifi
polypeptid
predict
bind
unusu
larg
number
hla
allel
briefli
score
analyz
aggreg
highscor
extend
n
ctermin
flank
predict
epitop
densiti
promiscu
epitop
fall
given
threshold
valu
particular
approach
map
epitop
also
use
discov
epibar
may
signatur
featur
highli
immunogen
promiscu
class
ii
epitop
exampl
promiscu
cell
cluster
contain
epibar
tetanu
toxin
shown
fig
singl
cell
epitop
cluster
usual
rang
amino
acid
length
contain
anywher
bind
motif
use
epimatrix
describ
clustim
score
particular
score
indic
signific
immunogen
potenti
de
groot
note
horizont
bar
high
z
score
posit
fig
observ
epibar
pattern
characterist
promiscu
epitop
author
integr
pattern
prospect
select
cluster
promiscu
epitop
also
exist
certain
degre
class
allel
laboratori
demonstr
crosspresent
peptid
within
hla
superfamili
superfamili
describ
sett
sidney
author
confirm
crossmhc
bind
present
cell
hiv
vaccin
studi
de
groot
et
al
one
limit
convent
vaccin
lesser
extent
natur
infect
immun
system
focus
strongli
mutabl
immunogen
viru
typic
viral
envelop
case
hiv
virus
vaccin
conserv
subdomin
epitop
shown
circumv
hierarchi
potenti
crossstrain
protect
ostrowski
et
al
nara
lin
like
manner
conserv
vaccin
may
provid
democrat
way
stimul
immun
respons
increas
number
target
cell
recognit
therebi
provid
help
antibodi
respons
despit
potenti
viral
variabl
santra
et
al
subbramanian
et
al
scherl
gerhard
scherl
gerhard
russel
liew
johansson
et
al
genet
variabl
pathogen
constitut
signific
challeng
effort
design
vaccin
driven
cellular
immun
respons
de
groot
et
al
de
groot
et
al
author
involv
develop
vaccin
includ
highli
conserv
crossclad
cell
epitop
conservatrix
algorithm
develop
applic
pars
input
sequenc
compon
string
length
string
may
determin
oper
search
input
dataset
match
segment
conservatrix
may
use
compar
string
deriv
differ
strain
organ
hepat
c
exampl
hiv
search
given
sequenc
usersuppli
target
sequenc
target
sequenc
may
input
specif
sequenc
code
pattern
thu
oper
use
wild
card
allow
one
amino
acid
residu
given
peptid
sequenc
amino
acid
x
limit
set
amino
acid
l
v
result
analysi
store
databas
may
brows
export
anoth
program
analysi
select
highli
conserv
epitop
regardless
distanc
ancestr
genom
identifi
sequenc
conserv
structur
function
reason
therefor
less
like
modifi
cours
evolut
peyerl
et
al
koibuchi
et
al
problem
viru
variabl
also
significantli
complic
select
epitop
populationcoverag
advantag
epitop
term
cluster
superfamili
promiscu
address
problem
author
develop
epiassembl
de
groot
et
al
identifi
set
overlap
conserv
promiscu
immunogen
epitop
assembl
extend
immunogen
consensu
sequenc
ic
see
fig
theori
proper
process
present
sequenc
would
allow
present
highli
conserv
peptid
context
one
mhc
result
peptid
pseudosequ
sinc
constitu
epitop
occur
correspond
posit
nativ
protein
thu
fulllength
immunogen
consensu
sequenc
necessarili
found
one
variant
sequenc
peptid
repres
sequenc
univers
case
hiv
exampl
use
ic
approach
design
peptidebas
vaccin
fullcomposit
ic
peptid
happen
exactli
conserv
individu
strain
hiv
peptid
repres
signific
percentag
circul
strain
everi
constitu
overlap
epitop
conserv
larg
number
rang
individu
strain
compar
immunogen
consensu
sequenc
randomli
select
counterpart
averag
contain
half
mani
bind
motif
cover
third
fewer
isol
develop
vaccin
equival
antigen
payload
use
convent
method
would
prohibit
expens
would
requir
includ
multipl
differ
variant
antigen
approach
use
identifi
highli
immunogen
epitop
hiv
vaccin
design
de
groot
et
al
focus
conserv
mhcpromiscu
helper
epitop
ic
approach
potenti
effici
overcom
genet
variabl
viru
host
one
advantag
idv
possibl
omit
deleteri
crossreact
epitop
perhap
famou
exampl
advers
effect
due
crossreact
self
observ
follow
vaccin
lyme
diseas
osp
protein
vaccin
recent
reengin
crossreact
epitop
remov
willett
et
al
context
work
peptid
select
vitro
evalu
evalu
homolog
human
protein
blast
sequenc
human
sequenc
databas
genbank
http
wwwncbinlmnihgov
blastim
autom
process
submit
sequenc
websit
featur
search
engin
blast
engin
ncbi
wwwncbinlmnihgovblast
default
blastim
blast
sequenc
nonredund
genbank
cd
translat
pdb
swissprot
pir
prf
blastim
assess
homolog
submit
sequenc
sequenc
protein
organ
patent
blast
hand
target
databas
sequenc
glean
patent
user
either
program
may
control
submiss
option
avail
interact
user
ncbi
case
result
record
databas
brows
export
summar
render
report
format
accord
author
standard
practic
peptid
share
greater
ident
peptid
contain
human
proteom
elimin
consider
vaccin
number
method
enhanc
epitopebas
vaccin
describ
implement
thomson
et
al
rodriguez
whitton
one
approach
align
epitop
protein
dna
vaccin
construct
string
bead
without
interven
sequenc
spacer
dna
plasmid
encod
individu
epitop
et
al
howev
lack
natur
flank
sequenc
rais
concern
proteolyt
process
may
compromis
junction
epitop
peptid
specif
peptid
interest
may
gener
result
process
godkin
et
al
address
concern
author
develop
vaccinecad
see
fig
algorithm
incorpor
evalu
junction
epitop
insert
spacer
breaker
requir
secret
process
tag
evalu
epitop
string
potenti
homolog
human
protein
fragment
import
compon
epitopedriven
vaccin
process
select
epitop
region
pathogen
present
mhc
molecul
cell
recognit
mhc
bind
motif
first
identifi
falk
pattern
amino
acid
peptid
known
promot
bind
peptid
contain
pattern
mhc
molecul
surfac
apc
falk
et
al
rotzschk
et
al
differ
mhc
molecul
differ
bind
motif
limit
set
mhc
ligand
present
context
given
mhc
consider
hla
allel
may
lead
concern
select
epitop
broad
coverag
popul
gulukota
delisi
sett
sidney
demonstr
epitopebas
vaccin
contain
epitop
restrict
select
supertyp
hla
provid
broadest
possibl
coverag
human
popul
furthermor
recent
studi
brander
walker
indic
may
even
greater
flexibl
bind
epitop
mhc
previous
recogn
also
consist
data
recent
present
frahm
et
al
inclus
promiscu
epitop
epitop
recogn
context
one
mhc
painabordignon
et
al
de
groot
et
al
sett
sidney
epitopedriven
vaccin
may
therefor
overcom
challeng
genet
restrict
immun
respons
addit
repertoir
possibl
mhcrestrict
epitop
recogn
individu
cell
shown
quit
variabl
even
hlamatch
individu
jameson
cruz
enni
gianfrani
et
al
bett
et
al
aggregatrix
new
algorithm
recent
develop
epivax
iter
search
combin
epitop
achiev
maxim
crossclad
represent
author
perform
analysi
hiv
epitop
shown
fig
evalu
hiv
peptid
individu
set
aggreg
coverag
strain
year
countri
origin
clade
seen
figur
set
highli
conserv
peptid
test
confirm
elispot
assay
cover
strain
given
year
strain
given
countri
strain
given
clade
hla
peptid
cover
clade
b
c
respect
remark
breadth
coverag
limit
set
hla
epitop
given
wellknown
abil
hiv
mutat
away
hla
nguyen
et
al
iversen
et
al
studi
immun
respons
therapeut
protein
author
observ
subjecttosubject
variat
cell
respons
close
relat
subject
hla
type
number
proteinderiv
peptid
match
subject
hla
describ
relationship
author
develop
metric
may
use
develop
epitopebas
vaccin
clinic
assess
immun
respons
vaccin
call
individu
cell
epitop
measur
item
item
calcul
subject
respond
given
epitop
sum
epimatrix
zscore
posit
peptid
hla
allel
given
subject
haplotyp
thu
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
eqalign
rm
item
score
hbox
epimatrix
score
peptid
hla
type
quad
hbox
epimatrix
score
peptid
hla
type
ldot
end
document
calcul
perform
larger
peptid
protein
sum
score
subject
hla
type
calcul
score
allow
individu
potenti
immunogen
predict
base
number
put
epitop
contain
protein
might
present
cell
base
hla
haplotyp
use
score
possibl
analyz
contribut
haplotyp
correspond
cell
respons
prospect
evalu
signific
correl
found
ifngamma
respons
given
antigen
item
score
individu
subject
data
publish
koren
et
al
r
p
addit
correl
item
score
patient
hla
also
observ
antibodi
titer
evalu
method
predict
individu
respons
vaccin
therapeut
protein
progress
defin
immunom
identifi
cell
epitop
confirm
immunogen
first
step
vaccin
develop
number
condit
extrins
mhcligand
interact
may
influenc
final
composit
epitop
ensembl
exampl
whether
predict
epitop
confirm
relat
quantit
express
sourc
protein
number
differ
epitop
deriv
protein
present
surfac
apc
wherri
et
al
amino
acid
flank
epitop
bergmann
et
al
shastri
serwold
gonzalez
livingston
et
al
proper
cleavag
trim
proteolyt
enzym
proteasom
process
pathway
van
kaer
et
al
york
et
al
chen
et
al
toe
et
al
exampl
like
endtoend
epitop
present
use
design
oxavi
hiv
gagepitop
vaccin
impair
present
epitop
immunogen
studi
vaccinecad
also
take
account
role
flank
residu
studi
conduct
murin
model
demonstr
residu
flank
mhc
class
epitop
strongli
influenc
deliveri
intact
epitop
tap
follow
proteasom
degrad
thomson
et
al
hozhutt
frommel
kloetzel
mo
et
al
addit
livingston
et
al
test
standard
spacer
sequenc
gpgpg
vaccin
construct
consist
mhciirestrict
thcell
epitop
use
spacer
disrupt
junction
epitop
might
compet
degrad
mhc
bind
g
p
unusu
carboxytermin
anchor
peptid
bind
class
ii
mhc
approach
use
construct
epitop
assay
respons
detect
major
epitop
livingston
et
al
francisella
tularensi
zoonot
bacterium
endem
certain
commun
martha
vineyard
massachusett
usa
known
rabbit
fever
tularemia
repres
potenti
danger
biolog
weapon
owe
high
degre
infect
eas
dissemin
capac
caus
sever
ill
despit
sever
decad
research
vaccin
tularemia
licens
public
use
review
tularemia
vaccin
see
mcmurri
et
al
activ
develop
epitopebas
tularemia
vaccin
combin
comput
immunolog
vitro
vivo
valid
mcmurri
et
al
start
point
vaccin
fulli
annot
f
tularensissubsp
tularensi
genom
publish
larsson
et
al
prototyp
vaccin
contain
class
ii
epitop
test
challeng
studi
hla
transgen
mice
vaccin
epimatrix
algorithm
util
identifi
highli
promiscu
cell
epitop
within
tularemia
genom
twentyf
class
iirestrict
epitop
select
synthes
screen
vitro
use
recombin
solubl
hla
class
ii
competitionbind
assay
describ
peptid
bound
high
affin
test
ex
vivo
elispot
assay
blood
obtain
f
tularensissubsp
tularensisexpos
individu
searchlight
analysi
also
perform
supernat
deriv
human
cell
cultur
stimul
peptid
use
panel
nine
cytokin
fortytwo
percent
peptid
bound
drb
like
bind
sever
allel
predict
use
clustim
algorithm
elispot
assay
show
posit
ifngamma
respons
individu
peptid
peptid
pool
nearli
human
studi
number
epitop
recogn
per
subject
rang
averag
per
subject
everi
peptid
test
everi
subject
peptid
elicit
robust
memori
respons
evalu
variou
assay
incorpor
vaccin
construct
test
challeng
studi
hla
transgen
mice
possibl
vaccin
tularemia
immunogen
studi
hla
transgen
mice
perform
use
multiclass
iiepitop
dna
construct
andor
peptid
repres
epitop
cell
respons
evalu
ifngamma
elispot
hla
transgen
mice
challeng
five
time
f
tularensi
lv
vaccin
mice
surviv
nonvaccin
mice
die
manuscript
prepar
result
demonstr
potenti
genomederiv
epitopebas
vaccin
protect
class
bioterror
pathogen
importantli
protect
observ
account
epitop
vaccin
conserv
lv
challeng
strain
epitop
found
significantli
immunogen
would
contribut
protect
challeng
result
consist
find
limit
set
epitop
may
suffici
induc
protect
immun
respons
moutaftsi
et
al
studi
use
wild
type
tularemia
plan
result
obtain
date
appear
indic
vaccin
design
origin
whole
genom
may
lead
develop
protect
epitopebas
vaccin
cervic
cancer
second
lead
caus
death
afflict
women
worldwid
cervic
patient
develop
persist
recurr
wide
metastat
diseas
prevent
vaccin
exist
hpv
need
therapeut
vaccin
treat
exist
case
hpv
especi
resourcepoor
area
access
prevent
vaccin
limit
cellular
immun
respons
believ
critic
effect
immun
respons
cancer
accordingli
epivax
pursu
develop
immunotherapeut
vaccin
would
focu
protein
primarili
express
either
carcinogenesi
order
maxim
immunogen
across
hpv
subtyp
strategi
involv
analyz
variant
strain
hpv
protein
sequenc
use
epimatrix
identifi
class
class
ii
hla
motif
match
conservatrix
identifi
motif
match
conserv
epiassembl
weav
togeth
conserv
immunogen
sequenc
full
immunogen
consensu
sequenc
ic
antigen
full
ic
vaccin
antigen
would
retain
fundament
structur
natur
occur
counterpart
howev
contain
better
epitop
would
occur
one
counterpart
author
identifi
five
conserv
epitop
stimul
signific
respons
elispot
ifng
assay
propos
vaccin
epitop
other
incorpor
natur
context
within
protein
could
deliv
dna
protein
primeboost
combin
preserv
natur
flank
region
surround
epitop
hope
retain
larg
part
natur
process
surround
hpv
protein
degrad
transport
present
occur
natur
infect
ic
approach
describ
illustr
fig
extend
full
natur
length
protein
indepth
review
similar
approach
pursu
influenza
see
mcmurri
et
al
epivax
hpv
vaccin
illustr
yet
anoth
aspect
vaccin
design
megatop
protein
reengin
increas
epitop
content
approach
alreadi
success
okazaki
et
al
case
variabl
virus
hcv
influenza
hiv
one
limit
convent
vaccin
natur
infect
immun
system
often
focus
strongli
mutabl
immunogen
idv
construct
altern
antigen
conserv
protect
circumv
problem
russel
liew
scherl
gerhard
scherl
gerhard
santra
et
al
subbramanian
et
al
addit
broaden
cell
repertoir
might
make
possibl
impair
viral
escap
decreas
viral
load
suffici
disrupt
transmiss
epitopedriven
vaccin
also
offer
distinct
advantag
vaccin
encod
whole
protein
antigen
sinc
epitop
safe
packag
rel
small
deliveri
vehicl
epitopedriven
approach
offer
platform
independ
deliveri
vehicl
peptid
dna
multiepitop
construct
modifi
select
midway
develop
process
multipl
conserv
epitop
addit
augment
efficaci
prevent
vaccin
could
provid
broad
univers
cellular
immun
known
crucial
contain
infect
although
perhap
ineffect
protect
infect
despit
advantag
number
reason
given
pathogendirect
epitopebas
vaccin
might
fail
reach
clinic
trial
protect
human
limit
number
epitop
express
vaccin
ie
poor
payload
quantiti
limit
conserv
epitop
lead
limit
coverag
variant
clinic
isol
limit
hla
popul
coverag
ie
poor
payload
qualiti
suboptim
vaccin
deliveri
andor
dearth
suitabl
anim
model
addit
concept
epitopedriven
vaccin
rel
novel
complet
genom
sequenc
avail
littl
decad
tool
process
data
vaccin
design
newer
experiment
valid
need
push
forward
vaccin
clinic
trial
emerg
promis
enabl
epitopebas
vaccin
claim
promin
place
vaccin
world
technolog
need
identifi
immunostimulatori
antigen
epitop
pathogen
genom
alreadi
well
develop
principl
focu
futur
research
area
like
finetun
technolog
expand
tailor
immun
respons
individu
exampl
develop
epitop
map
algorithm
dq
dp
class
ii
hla
allel
make
possibl
complet
character
immunom
inform
make
possibl
gener
comprehens
individu
cell
epitop
measur
item
base
individu
hla
genet
makeup
allow
research
identifi
priori
clinic
import
epitop
screen
clinic
cohort
subject
like
develop
target
immun
respons
furthermor
genomemap
tool
current
avail
yet
use
discov
b
cell
epitop
whether
protein
nonprotein
compon
carbohydr
lipid
antigen
immunoinformat
tool
current
avail
use
accur
predict
conform
b
cell
epitop
interact
antibodi
although
tool
refin
enshellseijff
et
al
thu
immunogen
identifi
use
silico
approach
must
evalu
vitro
also
appropri
challeng
model
prior
progress
vaccin
trial
protect
immun
respons
probabl
also
involv
engag
innat
immun
system
imposs
differenti
effect
nonprotect
epitop
cytokin
milieu
may
affect
outcom
immun
thu
limit
number
tollreceptor
agonist
imler
hoffmann
identifi
studi
conjunct
idv
futur
tollreceptor
signal
pathogenassoci
molecular
pattern
pamp
might
also
model
select
use
immunoinformat
tool
besid
antigen
identif
success
idv
reli
heavili
deliveri
technolog
area
continu
independ
matur
provid
import
lesson
epitopebas
vaccin
design
major
area
research
watch
includ
biolog
macromolecul
includ
cytokin
lipopeptid
polysaccharid
adjuv
particul
liposom
exosom
virosom
nanoparticl
cellbas
deliveri
system
develop
safe
effect
vaccin
emerg
infecti
diseas
influenza
season
pandem
hiv
tb
addit
cancer
associ
infecti
pathogen
hbv
hcv
urgent
achiev
public
health
prioriti
addit
vaccin
prevent
treatment
cancer
hold
enorm
promis
human
health
threat
bioterror
follow
event
septemb
provid
vaccinologist
persuas
argument
rapid
develop
vaccin
viral
bacteri
pathogen
includ
nih
categori
ac
biopathogen
list
http
emerg
infecti
diseas
ad
vaccin
wish
list
follow
outbreak
sever
acut
respiratori
syndrom
sar
guangdong
china
inde
month
follow
public
sarscoronaviru
sarscov
genom
marra
et
al
rota
et
al
research
began
map
vaccin
compon
use
new
bioinformat
immunoinformat
tool
coupl
improv
immunolog
techniqu
special
anim
model
new
vaccin
base
approach
current
evalu
anim
model
less
year
start
epidem
futur
vaccin
approach
may
need
move
away
whole
protein
vaccin
wide
rang
reason
multipl
antigen
epitop
vaccin
approach
illustr
could
one
way
elicit
sort
strong
respons
necessari
pathogen
follow
infect
context
therapeut
vaccin
approach
could
also
use
wide
rang
pathogen
genom
partial
complet
map
describ
chapter
group
activ
pursu
develop
epitopedriven
vaccin
hiv
de
groot
et
al
koita
et
al
franciscella
tularensi
helicobact
pylori
smallpox
progress
genomederiv
epitop
map
challeng
studi
less
one
year
vaccin
develop
program
epitopebas
whole
antigen
idv
begin
enter
clinic
trial
rel
disadvantag
may
cure
tinctur
time
one
reason
rel
pauciti
idv
clinic
develop
immunoinformat
tool
develop
vaccin
realli
evolv
last
year
averag
length
time
develop
vaccin
may
year
immunoinformat
tool
use
acceler
discoveri
preclin
stage
vaccin
develop
test
vaccin
anim
model
develop
clinic
trial
lengthi
process
like
idv
epitopebas
idv
begin
enter
clinic
trial
emerg
market
greater
number
year
